HCC Clinical Trial
Official title:
Association Between Serum Ferritin Level and Severity of Liver Disease and Development of HCC in Cirrhotic Patients.
Association between serum ferritin level and severity of liver disease and development of HCC in cirrhotic patients .
Status | Not yet recruiting |
Enrollment | 102 |
Est. completion date | October 1, 2023 |
Est. primary completion date | August 1, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients with liver cirrhosis of both sexes with and without HCC regardless of the aetiology of chronic liver disease Exclusion Criteria: - Patients less than 18 years Previously treated HCC patients with no evidence of recurrence or residual activity Subjects who had received blood transfusions or iron supplements during the previous 3 months. Other conditions associated with elevated serum ferritin e.g., malignancy other than HCC, iron overload syndromes, autoimmune disorders, chronic excess alcohol consumption and acute and chronic infections. Patients who will refuse to give a written consent, will be excluded from our study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394-424.doi: 10.3322/caac.21492 . Akinyemi
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Association between serum ferritin level and severity of liver disease and development of HCC in cirrhotic patients . | The relation between serum ferritin level and severity of liver disease and development of HCC in cirrhotic patients | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05458115 -
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
|
||
Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06434480 -
SBRT in HCC With Oligoprogression on Atezo-Bev
|
N/A | |
Completed |
NCT04542837 -
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05025592 -
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
|
||
Completed |
NCT04172506 -
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06024252 -
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
|
||
Not yet recruiting |
NCT05840133 -
Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
|
||
Terminated |
NCT02785874 -
Statin With Palliative Therapy for HCC
|
N/A | |
Not yet recruiting |
NCT02715492 -
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
|
Phase 3 | |
Completed |
NCT02985034 -
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
|
N/A | |
Not yet recruiting |
NCT06069947 -
SALT for Liver Cirrhosis With HCC
|
N/A | |
Recruiting |
NCT05581004 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Suspended |
NCT02935478 -
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
|
N/A | |
Recruiting |
NCT05592171 -
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
|
N/A | |
Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
Recruiting |
NCT05544253 -
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
|
Phase 2/Phase 3 | |
Recruiting |
NCT06184152 -
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
|
||
Completed |
NCT02675920 -
A Study of HCC High Risk Group Using Two Surveillance Tools
|